Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$119.02 USD

119.02
2,750,456

-1.12 (-0.93%)

Updated Aug 14, 2025 02:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (146 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

What's in the Cards for Sarepta (SRPT) This Earnings Season?

by Zacks Equity Research

Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive second-quarter sales.

Zacks Equity Research

What's in the Cards for Pfizer (PFE) This Earnings Season?

by Zacks Equity Research

While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q2 sales, genericization of some older drugs will hurt the same.

Zacks Equity Research

What's in the Cards for Amarin (AMRN) This Earnings Season?

by Zacks Equity Research

Amarin's (AMRN) cardiovascular drug, Vascepa is expected to drive sales in the second quarter.

Zacks Equity Research

Will Strong HIV Sales Drive Gilead's (GILD) Q2 Earnings?

by Zacks Equity Research

Investors are expected to focus on the HIV franchise's performance and other pipeline updates, when Gilead (GILD) reports second-quarter 2019 results.

Zacks Equity Research

Vertex (VRTX) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the adoption of its newest CF drug Symdeko and the update on its NDA filing for the VX-445 triple combination regimen.

Zacks Equity Research

Can Newer Drugs Help Amgen (AMGN) Beat on Earnings in Q2?

by Zacks Equity Research

While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on second-quarter sales.

Zacks Equity Research

Will Strong Jakafi Sales Drive Incyte (INCY) Q2 Earnings?

by Zacks Equity Research

Investors will primarily focus on Jakafi sales and pipeline updates, when Incyte (INCY) reports second-quarter 2019 results.

Zacks Equity Research

5 Drug/Biotech Stocks Set to Beat Earnings Estimates in Q2

by Zacks Equity Research

We take a look at the overall drug/biotech sector's performance and five stocks that are poised to beat on earnings in the second quarter of 2019.

Zacks Equity Research

Acorda (ACOR) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Acorda's (ACOR) second-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.

Zacks Equity Research

What's in the Cards for AcelRx (ACRX) This Earnings Season?

by Zacks Equity Research

AcelRx (ACRX) will provide updates on the launch and sales of Dsuvia when it releases second-quarter 2019 results.

Zacks Equity Research

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $66.64, marking a +0.36% move from the previous day.

Zacks Equity Research

Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded

by Zacks Equity Research

Key highlights of the past week include earnings update, collaborations and other pipeline news.

Zacks Equity Research

Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (GILD) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Eli Lilly (LLY) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q2.

Zacks Equity Research

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

by Zacks Equity Research

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be on the higher side in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.

Zacks Equity Research

Is a Beat in Store for Repligen (RGEN) This Earnings Season?

by Zacks Equity Research

On Repligen's (RGEN) second-quarter earnings call, investor focus will be on its advancement with the proposed acquisition of C Technologies, Inc.

Zacks Equity Research

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AMAG (AMAG) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

We expect AMAG (AMAG) to provide updates on its revenue-driving products, when it reports second-quarter earnings.

Zacks Equity Research

What's in Store for Anika Therapeutics' (ANIK) Q2 Earnings?

by Zacks Equity Research

On Anika Therapeutics' (ANIK) second-quarter earnings call, investor focus will be on its progress with the U.S. approval of its orthopedic product Cingal.

Sweta Killa headshot

Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy

by Sweta Killa

With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.

Zacks Equity Research

Alexion (ALXN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Soliris' solid performance is likely to reflect in Alexion's (ALXN) second-quarter 2019 results.

Zacks Equity Research

Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?

by Zacks Equity Research

While sales of Biogen's (BIIB) MS franchise are expected to decline in the second quarter of 2019, Spinraza U.S. sales may improve.

Zacks Equity Research

Gilead Sciences (GILD) Stock Moves -0.03%: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $66.92 in the latest trading session, marking a -0.03% move from the prior day.

Zacks Equity Research

Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study

by Zacks Equity Research

Key highlights of the past week include collaborations and other pipeline updates.

Zacks Equity Research

Company News for Jul 16, 2019

by Zacks Equity Research

Companies In The News Are: SYMC,AVGO,GLPG,GILD,BA,AAL,UNIT